Kornimate/medical-research-clean huggingface dataset:
the effect of virtual reality glasses used during burn dressing in children on pain, anxiety and fear

Conditions: Randomized

Summary: this work; it was planned as a randomized controlled study to determine the effect of watching cartoons with virtual reality glasses during burn dressing of children aged 5-10 years who applied to the training and research hospital burn unit polyclinic on the feeling of pain, anxiety and fear in children.

the study will be applied to children in the 5-10 group who will undergo burn dressing. during the dressing, children will be watched cartoons with virtual reality glasses and pain, anxiety and fear will be looked at before and after the dressing. the children in the control group will be given routine applications of the clinic.

Eligibility criteria:
inclusion criteria: * the child and family agree to participate in the research, * the child does not have a disease that causes chronic pain, * the child is between the ages of 5-10, * 1st and 2nd degree burns of less than 10% of the body surface area of the child, * local burn, no facial burn * the child has no mental or neurological disability * failure to intervene in the child with general anesthesia * the child has no eye problems exclusion criteria: * child and family refusal to participate in the study * 3rd and 4th degree burns of more than 10% of the body surface area of the child, * the child is less than 5 years old and over 10 years old * the child has a mental or neurological disability * intervention of the child with general anesthesia * the child has an eye problem
nuclear imaging for subtype diagnosis of primary aldosteronism

Conditions: Primary Aldosteronism

Summary: this study is to evaluate the accuracy of a novel radiopharmaceutical tracer, para-chloro-2-\[18f\]fluoroethyl etomidate (ceto), used with positron emission tomography (pet) and computed tomography (ct), as a way to subtype unilateral vs. bilateral forms of primary aldosteronism, compared to avs as a reference gold standard.

this is a phase ii study (with targeted recruitment of 30 participants) designed to evaluate the accuracy of a novel radiopharmaceutical tracer, para-chloro-2-\[18f\]fluoroethyl etomidate (ceto), used with positron emission tomography (pet) and computed tomography (ct), as a way to subtype unilateral vs. bilateral forms of primary aldosteronism, compared to avs as a reference gold standard. subjects consenting to study participation will receive the \[18-f\] ceto followed by the pet/ct scan.

Eligibility criteria:
inclusion criteria: * individuals with hypertension * individuals with an elevated screening adrenal renin ratio (arr) * individuals with or without spontaneous or diuretic-induced hypokalemia, and/ or plus a discrete adrenal nodule or nodules (1 cm or greater) with concordant lateralization on avs. exclusion criteria: * individuals with chronic kidney disease (estimated glomerular filtration rate \<40 ml/min/1.73m2), * individuals with a history of uncontrolled severe hypertension (\>180/110 mmhg), severe uncontrolled diabetes, suspected or proven hypercortisolism (e.g., cortisol-secreting adrenal adenoma), or individuals with an anatomical disease of the liver (e.g., hepatic adenoma or focal nodular hyperplasia) * allergy to intravenous contrast, coagulopathy, use of chronic corticosteroids. * pregnancy, lactation, and pheochromocytoma.
role of statin therapy in prevention of anthracycline-induced cardiotoxicity

Conditions: Doxorubicin Induced Cardiomyopathy

Summary: this study aims at evaluating the role of atorvastatin in prevention of anthracycline induced cardiotoxicity

the study participants are female patients with breast cancer receiving anthracycline based chemotherapy. they will be divided into 2 groups , the first group will receive 40 mg oral atorvastatin through out the study , while the other group will receive a placebo. full echocardiographic study including 3d echocardiography will be done to all patients before starting their chemotherapy and after 6 months.

Eligibility criteria:
inclusion criteria: * female patients diagnosed with histology proven breast cancer with an indication to primary systemic therapy or adjuvant regimens based on anthracyclines exclusion criteria: * patients with impaired lv systolic function (ef below 50%) * patients with severe valvular heart disease * patients previously diagnosed with coronary artery disease * patients with baseline elevated liver enzymes * patients with prior chemotherapy or radiation therapy * pregnant females

Keywords: anthracyclines doxorubuicn cardiotoxicity
levels of inflammation in middle east people with cardiovascular disease with/without kidney disease

Conditions: Systemic Inflammation (hsCRP)

Summary: this study will collect medical and background information from participants with diseases that affect the heart and blood vessels (cardiovascular disease) with/without kidney disease. the aim of the study is to assess the number of people with high levels of systemic inflammation among middle east people with cardiovascular with/without kidney disease. systemic inflammation means that it occurs throughout the body. participation in this study only requires a single visit at the clinic/hospital/medical institution. participants will continue their normal care and will not get any treatment as part of this study.


Eligibility criteria:
inclusion criteria: 1. informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 2. male or female, age above or equal to 18 years at the time of signing informed consent. 3. diagnosed with ascvd+ckd and/or hf (pef or mref) exclusion criteria: 1. previous participation in this study. participation is defined as having given informed consent in this study. 2. current participation (i.e., signed informed consent) in any other interventional clinical study. 3. any hospitalization or unplanned visit within the last 60 days (including exacerbation of chronic disease with hospitalization). 4. clinical evidence, or suspicion of, active infection within the last 60 days. 5. mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
a pilot study assessing impulsivity in patients with huntington's disease on xenazine (tetrabenazine)

Conditions: Huntington's Disease

Summary: the purpose of this research study is to see if tetrabenazine, which is commonly used to treat huntington's disease (hd), reduces the problems of impulsivity that are common in patients with hd. investigators will also see how the medicine affects aspects of thinking and mood.

this study is an open-label assessment of behavioral symptoms including depression, impulsivity, and suicidal ideations in patients prior to, and after, taking a stable dose of tbz for huntington's disease. all subjects will be evaluated with tests of depression (beck depression scale), impulsivity (quip, bis-11, and computerized impulsivity scales), and suicidal ideation (columbia suicide scale) as a safety measure before they actually start taking tbz. since there is a significant lack of awareness of emotional and cognitive symptoms (anosagnosia) in patients with hd, collateral sources will be asked to fill out similar questionnaires based on their knowledge and observation of the patient. patients and collaterals will be asked to return to the clinic for an identical evaluation plus adverse events, after they have been on a stable dose of tbz for 4 weeks, which would be 8 ± 1 week after initiating tbz. patients will be titrated over 3-5 weeks to best dose as determined by the investigator, up to a maximum of 75 mg/day. as patients are titrating, there will be several telephone contacts conducted. the initial dose will be 12.5 mg bid. best dose will be largely determined by adverse events and subjective efficacy. determination of best dose will include two scheduled phone calls and others as needed. other medications will remain stable between visits.

Eligibility criteria:
inclusion criteria: * for huntington's disease (hd) patients only--definite hd as indicated by positive gene testing or typical symptoms in the context of family history of hd. * a moderate degree of impulsivity as measured by the barrat impulsivity scale (bis). (\>65) * must be symptomatic in the opinion of the investigator. standard clinical criteria for symptomatic hd will be employed, any motor signs c/w hd, usually chorea. * patient is cognitively alert and able to answer/understand. exclusion criteria: * patient requires the assistance of another person to walk, or is non-ambulatory. * patient is severely impaired cognitively. * patients taking neuroleptic (dopamine blocking) medications within the past 14 days. * patient is actively suicidal, has untreated or inadequately treated depression, has impaired hepatic function, is taking mao inhibitors or is taking reserpine or has been off of reserpine for less than 20 days
a 10-12 week study to evaluate the safety and efficacy of 320 mg valsartan and 80 mg simvastatin in combination and as monotherapies in treating hypertension and hypercholesterolemia

Conditions: HYPERTENSION; HYPERCHOLESTEROLEMIA

Summary: this 10-12 week study will provide data on the safety and efficacy of using 320 valsartan and 80 mg simvastatin together compared to using either one alone in lowering blood pressure and ldl cholesterol. after discontinuing current drug therapies for hypertension and hypercholesterolemia, patients will be given 320mg valsartan+80mg simvastatin, 320mg valsartan+placebo, or 80mg simvastatin+placebo..


Eligibility criteria:
inclusion criteria: * essential hypertension * elevated ldl-c cholesterol * using stable dose of hmg coa reductase inhibitor (statin) for 3+ months exclusion criteria: * severe hypertension * evidence of history or current heart disease * history of stroke or myocardial infarction * dislipidemia or hypertension due to secondary causes * uncontrolled diabetes or insulin other protocol-defined exclusion criteria may apply.

Keywords: hypertension hypercholesterolemia blood pressure cholesterol valsartan simvastatin
clinical efficacy and safety of perampanel monotherapy in the treatment of children with focal epilepsy

Conditions: Focal Epilepsy

Summary: this project is a multicenter prospective study. by retrieving outpatient medical records and collecting clinical data of epilepsy patients, the efficacy and safety of single-drug perampanel in patients with focal epilepsy were analyzed.

this project is a multicenter prospective study. the selected case population was given the oral antiepileptic drug perampanel for 12 months, and the seizure control (complete control, markedly effective, effective, ineffective, worsening), eeg changes (normal, effective, ineffective), and adverse reactions were analyzed, so as to provide a basis for perampanel monotherapy in children with focal epilepsy.

Eligibility criteria:
inclusion criteria: (1) clinical diagnosis of focal epilepsy; (2) take anti-epileptic drugs as prescribed by your doctor; (3) epilepsy patients diagnosed with focal epilepsy with or without generalized seizures, and monitoring for ≥12 months; (4) newly diagnosed epilepsy patients, or only taking 1-2 other aeds, without regular antiepileptic treatment, the efficacy is not good, after using perampanel, gradually stop aeds for 8 weeks. for perampanel monotherapy; (5) the number of seizures ≥ 1 in the first 3 months of enrollment. exclusion criteria: (1) syncope (2) pseudo-seizure(3)transient ischemic attack
pancreas cancer surveillance using an abbreviated mri

Conditions: Pancreas Cancer

Summary: this study aims to establish a prospective cohort of developing pancreas cancer and surveillance mri protocol. with the focused surveillance protocol, we perform surveillance for pancreas cancer for five years to estimate the risk of pancreas cancer and the clinical feasibility of the surveillance mri.


Eligibility criteria:
inclusion criteria: * on follow-up due to first degree-family history of pac * or on follow-up for bd-ipmn (\>= 2 cm) or main-duct type ipmn (\> 5 mm) * and signed informed consent exclusion criteria: * contra-indication of performing mri * not satisfying the selection criteria. * previously diagnosed with pancreatic malignancy * pregnancy or planning pregnancy

Keywords: pancreas cancer intraductal papillary mucinous neoplasm magnetic resonance imaging
four year weight change of cornell students

Conditions: Weight Gain

Summary: examining the effect of daily self-weighing on the ability of student to prevent from gaining weight during their four years at cornell.

a group of freshman volunteers were randomly assigned to one of two groups. both groups were given an internet based scale (withings). the experimental group was asked to weigh themselves daily. the controls were asked to weigh themselves three times within one week every six months in response to being contacted by our researchers.

Eligibility criteria:
inclusion criteria: * healthy exclusion criteria: * pregnancy

Keywords: among college students
the effect of midazolam on fluid responsiveness in septic patients

Conditions: Septic Shock

Summary: fluid resuscitation remains the foundation for septic treatment.the evaluation of fluid responsiveness has significance in volume resuscitation for septic shock patients. as the sedative which is commonly used in icu, midazolam is supposed to change fluid responsiveness for the pharmacological effect of venodilation. however, the hypothesis has not been certified clinically. in this research, the investigators aim to test the hypothesis that midazolam can increase fluid responsiveness(using passive leg raising test) in septic shock patients.


Eligibility criteria:
patients are included if they meet the following inclusion criteria: 1. above 18 years old 2. endotracheal intubated and mechanical ventilated 3. awake, can communicate with researchers 4. diagnosed as septic shock. the definition of septic shock was clarified in year 2001 accp/sccm guidelines 5. within 24 hours after the egdt resuscitation goals are achieved 6. informed consent are signed. exclusion criteria 1. under 18 years old 2. intra-abdominal hypertension 3. central nerves system dysfunction 4. heart failure and other cardiac dysfunction such as cardiac conduction block,acute coronary syndrome, cardiogenic shock 5. proof of volume overload or contradiction of fluid infusion 6. existence of arterial aneurysm, serious valvular disease,extensive peripheral vascular occlusion disease and insertion of artificial pacemaker

Keywords: septic shock sepsis fluid responsiveness midazolam propofol haemodynamics
study on ceftazidime and sulbactam sodium for injection (2:1) for treatment of respiratory and urinary tract infection

Conditions: Respiratory Tract Infections; Urinary Tract Infections

Summary: in the proposed study, the investigators plan to evaluate the efficacy and safety of ceftazidime sodium and sulbactam sodium for injection(2:1) for the treatment of respiratory and urinary tract acute bacterial infection.

ceftazidime is a third-generation cephalosporins. ceftazidime sodium and sulbactam sodium for injection (2:1)plays a therapeutic role by the former inhibiting bacterial cell wall synthesis，the latter making irreversible competitive inhibition of β-lactamase.the antimicrobial effect of ceftazidime can be enhanced by the two combined. the compound specifically aims to the mechanism of bacterial resistance, extending the life of ceftazidime in the treatment-resistant pathogen infections.

Eligibility criteria:
inclusion criteria: 1. patients who qualify for moderate and severe acute respiratory or urinary tract bacterial infection of acute bacterial infections need for systemic antibiotic therapy. 2. hospital patients or good compliance clinic patients, who were more than 18 years old and less than 70 years old, gender: both. 3. patients who do not take other antibiotic medications before screening period. 4. patients who have no severe liver, kidney and hematopoietic system of diseases (both ast and alt are less than 1.5 times of the upper limit of normal and cr is in normal range) 5. pathogenic bacteria was resistant to ceftazidime and sensitive to both of test drugs and contrast drugs. 6. women of childbearing was to be negative pregnancy test and agree to take contraceptive measures during the trial. 7. patients were volunteers and signed informed consent from. exclusion criteria: 1. patients were hypersusceptibility to the test drug or other penicillins ,β-lactamase inhibitor 2. pathogenic bacteria was sensitive to ceftazidime or resistant to ceftazidime,test drugs and control drugs. 3. patients who need to take other antibiotic medicine because of concurrent infection. 4. patients who took medicine which affected efficacy evaluations and safety evaluations such as aspirin, indomethacin, phenylbutazone, sulfanilamide, disulfiram and probenecid in the trial. 5. patients who took risks of severe drug interactions because of drug combination. 6. patients who were complicated by other diseases and thought to affect efficacy evaluations or poor compliance. 7. pregnant and lactating women 8. drug addicts and alcoholics. 9. patients who once was selected in this trial. 10. patients who participated in other clinical trials in the past three months.

Keywords: respiratory and urinary tract infections ceftazidime and sulbactam sodium for injection (2:1) phase ⅱ
evaluation on the safety of ticagrelor among chinese acs patients

Conditions: Acute Coronary Syndrome (ACS)

Summary: the primary objective is to describe the safety and tolerability of ticagrelor, by assessment of adverse events (characteristics, reporting rate, severity, relationship and risk factors), especially the bleeding events as defined in 8.1 and other serious adverse events (saes) during 1-year follow up in chinese acute coronary syndrome (acs) patients.

the trial is a multi-centre, prospective cohort, non-interventional study to be conducted in the department of cardiology from approximately 20 tier-2 or 3 hospitals, china. the study requires chinese subjects aged over 18, diagnosed as acs and treated with ticagrelor at least one tablet from the department of cardiology in the around 20 tier-2 or 3 hospitals. the subjects will be tracked up to 1 month after the discontinuation of ticagrelor for ae events and 1 year after enrollment for major cardiovascular events. this is an observational study. the prescribing doctor is in charge of prescribing or discontinuation ticagrelor. the investigator in an observational study may not intervene in the treatment. all 1000 subjects' related data will be collected

Eligibility criteria:
inclusion criteria: * 1. provision of informed consent prior to any study specific procedures 2. chinese female or male aged at least 18 years 3. index event of non-st or st segment elevation acs. 4. taken with ticagrelor at least one tablet before enrollment. exclusion criteria: -1. participation in another clinical study with an investigational product during the last 6 months. 2. previous enrolment in the present study; 3. allergy or any other contraindication to ticagrelor as described in ticagrelor china pi.

Keywords: acs
travoprost five day posology study

Conditions: Open-angle Glaucoma (OAG); Ocular Hypertension

Summary: the purpose of this study is to determine the safety and efficacy of three concentrations of travoprost ophthalmic solution (groups a, b and c) administered eight times daily.


Eligibility criteria:
inclusion criteria: 1. either sex and any race/ethnicity, ≥18 years old 2. diagnosed with open-angle glaucoma, and/or ocular hypertension 3. meets the following iop entry criteria: * mean iop ≥ 24 millimeters mercury (mmhg) in at least 1 eye, with the same eye qualifying at 8 am on both the eligibility visit (day 0) and day 1 * mean iop ≤ 36 mmhg in both eyes at 8 am and 8 pm at the eligibility visit (day 0), and at 8 am on day 1 4. satisfies all informed consent requirements; able to read, sign and date the informed consent exclusion criteria: 1. females of childbearing potential not meeting protocol conditions 2. angle grade less than grade 2 in either eye 3. cup to disc ratio greater than 0.8 (horizontal or vertical measurement) in either eye 4. severe central visual field loss in either eye 5. any abnormality preventing reliable applanation tonometry in either eye 6. hypersensitivity to prostaglandin analogues or to any component of the study medication
evaluation of surgical complications

Conditions: Post Operative Complications

Summary: surgical complications may be very serious and are often under-reported. the aim of this study it to document and study all the postoperative complications at our department during one year using a novel grading system.


Eligibility criteria:
inclusion criteria: * all patients undergoing surgery at our department. * no gender difference. exclusion criteria: * age - less than 18.

Keywords: surgery post operative complications length of stay
a study on the prevalence of obstructive sleep apnea in patients with type ii diabetes mellitus

Conditions: Obstructive Sleep Apnea; Diabetes Mellitus

Summary: osa is prevalent among patients with type ii dm

obstructive sleep apnea (osa) has been reported to be common (prevalence ranged from 23-86%) in previous studies involving caucasian diabetic patients. the investigators aim at finding out the prevalence of osa in chinese diabetic patients and identify the clinical predictors associated with osa. recruited subjects will undergo overnight polysomnography, anthropometric measurements, blood tests including glycosylated hemoglobin, renal function, glucose level, blood pressure measurement both during the clinic visit and after admission for in-laboratory sleep study.

Eligibility criteria:
inclusion criteria: * patients, age 18 - 75, with type 2 diabetes mellitus, including those on diet, on oral-hypoglycaemic agents or on insulin * patients who are able to give written consent to undergo polysomnography exclusion criteria: * patients who are unable or unwilling to give written consent to participate in the study * patients with unstable medical illness or poor functional performance * patients with recent myocardial infarction or hospital admission for congestive heart failure or cardiac arrhythmia in the past three months * patients on renal replacement therapy for diabetic nephropathy or chronic renal failure, or plan to start renal replacement therapy in the coming six months * patients suffered from recent stroke in the past six months or previous history of stroke with significant focal neurological deficit * patients with type i diabetes * pregnant lady or lactating women

Keywords: obstructive sleep apnea prevalence diabetes mellitus chinese
use of masks on metabolic parameters and inspiratory muscle strength during aerobic exercise

Conditions: Masks

Summary: the purpose of this study will be to assess the effects of the use of masks on inspiratory muscle strength, metabolic parameters, heart rate, subjective perception of effort and the sensation of dyspnea before, during and after an aerobic test of 30 minutes long and a fixed load at lactate threshold. a randomized study of repeated measures will be carried out. a total sample of 35 active participants will be recruited. all participants will carried out a lactate threshold test and then 3 visits to the laboratory (separated at least 48 hours from each other) in order to perform 3 test of 30 minutes long without mask, with a surgical mask or with a ffp2 respirator (in a randomized order) at an intensity around lactate threshold intensity. maximal inspiratory pressure, oxygen saturation, heart rate, blood lactate concentration, subjective perception of effort and dyspnea will be assessed before, during and after the 3 fixed intensity tests.


Eligibility criteria:
inclusion criteria: * carrying out at least 2 days of physical activity per week exclusion criteria: * cardiac disease * pulmonary disease * chronic inflammatory disease * sedentary behaviour